Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2021-12-15 Capital/Financing Update
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Notice under Section 708(A) of the Corporations Act 2 pages 152.3KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act, which relates to the issuance of securities without disclosure under Part 6D.2 of the Corporations Act. It provides details about the securities issued, including class, ASX code, date, and number of shares issued. The document is short (3163 characters) and serves as a formal announcement to the ASX regarding a capital raising event without a disclosure document. It does not contain financial statements or detailed financial analysis, nor is it a report or presentation. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising or capital structure changes.
2021-12-15 English
OrthoATI Tendon Clinical Study Success 24 pages 1.5MB
Capital/Financing Update Classification · 85% confidence The document is a detailed announcement of clinical study results for a medical treatment product (OrthoATI™) by Orthocell Limited. It includes extensive clinical trial data, patient outcomes, statistical significance, and future commercial plans. The text is not a financial report, earnings release, or regulatory filing but rather a scientific and commercial update on a clinical study. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a corporate announcement focused on clinical trial success and commercial strategy, which is typical of a Capital/Financing Update or a general corporate announcement. However, since it discusses clinical study results and commercial plans rather than financing or capital structure changes, the best fit is Capital/Financing Update (CAP) as it relates to advancing commercialization and FDA engagement, which are capital and financing related activities. The document length is substantial and contains detailed data, so it is not a mere announcement of a report (RPA) or a regulatory filing (RNS).
2021-12-07 English
Trading Halt 2 pages 567.4KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Orthocell Limited requesting a trading halt on its shares pending the release of an announcement related to study results. It references ASX Listing Rule 17.1 and is dated 7 December 2021. The content is brief (1956 characters) and does not contain any financial data, report content, or detailed analysis. It is clearly an announcement about a trading halt, not a financial report or detailed disclosure. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2021-12-06 English
Application for quotation of securities - OCC 6 pages 27.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an application for quotation of securities on the ASX, detailing the issuance and conversion of options into ordinary fully paid shares. It includes specifics about the number of securities, issue dates, and the nature of the securities being quoted. This type of document is related to changes in the company's capital structure, specifically the issuance and quotation of new shares resulting from option exercises. It is not a financial report, earnings release, or management discussion, nor is it a regulatory announcement about voting or board changes. The document fits the category of Share Issue/Capital Change announcements, as it concerns the issuance and quotation of new shares following option conversion.
2021-11-17 English
Notice under Section 708(A) of the Corporations Act 2 pages 152.2KB
Capital/Financing Update Classification · 95% confidence The document is a notice under Section 708A(5)(e) of the Corporations Act, which relates to the issuance of securities without disclosure under Part 6D.2 of the Corporations Act. It provides details about the securities issued, including class, ASX code, date, and number of shares issued. The document is short (3163 characters) and serves as a formal announcement to the ASX and investors about the issuance of shares without a disclosure document. It does not contain financial statements, management discussion, or detailed financial data. It is not a full report but a regulatory announcement about capital raising activity. Therefore, it fits best under Capital/Financing Update (CAP).
2021-11-17 English
Ortho-ATI Shoulder Tendon Study Database Lock 3 pages 227.4KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the locking of the database for the Ortho-ATI shoulder tendon study and the submission of data for analysis, with top line results expected in Q4 2021. It discusses the study design, market opportunity, and next steps but does not contain any financial statements, detailed financial results, or regulatory filings. It is an update on clinical trial progress and company developments rather than a formal financial report or regulatory filing. The document length is about 10,299 characters, which is relatively short and reads like a corporate announcement or update. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other formal financial or regulatory filing. It is also not a presentation or transcript. Given the content and format, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous company announcements that do not fit other categories.
2021-11-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.